vs
Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and AMREP CORP. (AXR). Click either name above to swap in a different company.
AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $13.0M, roughly 1.1× Aquestive Therapeutics, Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -244.8%, a 266.4% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs 9.7%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-8.6M). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs -13.6%).
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
AQST vs AXR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.0M | $14.6M |
| Net Profit | $-31.9M | $3.1M |
| Gross Margin | 55.2% | — |
| Operating Margin | -221.6% | 20.6% |
| Net Margin | -244.8% | 21.6% |
| Revenue YoY | 9.7% | 93.8% |
| Net Profit YoY | -86.8% | 338.9% |
| EPS (diluted) | $-0.26 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.6M | ||
| Q4 25 | $13.0M | $9.4M | ||
| Q3 25 | $12.8M | $17.9M | ||
| Q2 25 | $10.0M | $11.2M | ||
| Q1 25 | $8.7M | $7.5M | ||
| Q4 24 | $11.9M | $11.9M | ||
| Q3 24 | $13.5M | $19.1M | ||
| Q2 24 | $20.1M | $19.5M |
| Q1 26 | — | $3.1M | ||
| Q4 25 | $-31.9M | $1.2M | ||
| Q3 25 | $-15.4M | $4.7M | ||
| Q2 25 | $-13.5M | $3.9M | ||
| Q1 25 | $-22.9M | $717.0K | ||
| Q4 24 | $-17.1M | $4.0M | ||
| Q3 24 | $-11.5M | $4.1M | ||
| Q2 24 | $-2.7M | $4.1M |
| Q1 26 | — | — | ||
| Q4 25 | 55.2% | — | ||
| Q3 25 | 64.8% | — | ||
| Q2 25 | 54.4% | — | ||
| Q1 25 | 58.1% | — | ||
| Q4 24 | 61.9% | — | ||
| Q3 24 | 67.2% | — | ||
| Q2 24 | 77.5% | — |
| Q1 26 | — | 20.6% | ||
| Q4 25 | -221.6% | 11.9% | ||
| Q3 25 | -89.6% | 34.4% | ||
| Q2 25 | -113.6% | 31.7% | ||
| Q1 25 | -222.1% | 5.7% | ||
| Q4 24 | -114.4% | 26.4% | ||
| Q3 24 | -61.2% | 26.1% | ||
| Q2 24 | 0.3% | 23.9% |
| Q1 26 | — | 21.6% | ||
| Q4 25 | -244.8% | 12.8% | ||
| Q3 25 | -120.6% | 26.3% | ||
| Q2 25 | -135.4% | 34.8% | ||
| Q1 25 | -263.0% | 9.5% | ||
| Q4 24 | -143.7% | 33.9% | ||
| Q3 24 | -85.0% | 21.3% | ||
| Q2 24 | -13.7% | 21.2% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | $-0.26 | $0.22 | ||
| Q3 25 | $-0.14 | $0.87 | ||
| Q2 25 | $-0.14 | $0.73 | ||
| Q1 25 | $-0.24 | $0.13 | ||
| Q4 24 | $-0.18 | $0.75 | ||
| Q3 24 | $-0.13 | $0.76 | ||
| Q2 24 | $-0.03 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $50.0M |
| Total DebtLower is stronger | $27.5M | $21.0K |
| Stockholders' EquityBook value | $-33.7M | $139.4M |
| Total Assets | $160.4M | $143.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | $129.1M | $48.9M | ||
| Q2 25 | $60.5M | $39.5M | ||
| Q1 25 | $68.7M | $36.9M | ||
| Q4 24 | $71.5M | $40.1M | ||
| Q3 24 | $77.9M | $40.4M | ||
| Q2 24 | $89.9M | $29.7M |
| Q1 26 | — | $21.0K | ||
| Q4 25 | $27.5M | $23.0K | ||
| Q3 25 | $45.0M | $25.0K | ||
| Q2 25 | $45.0M | $26.0K | ||
| Q1 25 | $45.0M | $29.0K | ||
| Q4 24 | $32.5M | $32.0K | ||
| Q3 24 | $45.0M | $34.0K | ||
| Q2 24 | $45.0M | $35.0K |
| Q1 26 | — | $139.4M | ||
| Q4 25 | $-33.7M | $136.0M | ||
| Q3 25 | $-4.1M | $134.7M | ||
| Q2 25 | $-72.6M | $130.0M | ||
| Q1 25 | $-60.9M | $126.0M | ||
| Q4 24 | $-60.2M | $125.1M | ||
| Q3 24 | $-45.4M | $122.2M | ||
| Q2 24 | $-35.5M | $118.0M |
| Q1 26 | — | $143.9M | ||
| Q4 25 | $160.4M | $140.1M | ||
| Q3 25 | $163.6M | $140.7M | ||
| Q2 25 | $93.7M | $133.8M | ||
| Q1 25 | $102.2M | $128.9M | ||
| Q4 24 | $101.4M | $129.1M | ||
| Q3 24 | $110.0M | $127.0M | ||
| Q2 24 | $117.6M | $122.8M |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.5M | $5.4M |
| Free Cash FlowOCF − Capex | $-8.6M | $5.4M |
| FCF MarginFCF / Revenue | -65.7% | 37.0% |
| Capex IntensityCapex / Revenue | 0.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-53.0M | $20.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-8.5M | $-4.3M | ||
| Q3 25 | $-12.6M | $9.5M | ||
| Q2 25 | $-7.9M | $10.2M | ||
| Q1 25 | $-23.4M | $-3.2M | ||
| Q4 24 | $-6.5M | $-182.0K | ||
| Q3 24 | $-11.9M | $10.7M | ||
| Q2 24 | $-7.0M | $10.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-8.6M | $-4.3M | ||
| Q3 25 | $-12.9M | $9.5M | ||
| Q2 25 | $-8.0M | $9.7M | ||
| Q1 25 | $-23.5M | $-3.3M | ||
| Q4 24 | $-6.5M | $-268.0K | ||
| Q3 24 | $-12.0M | $10.7M | ||
| Q2 24 | $-7.0M | $10.3M |
| Q1 26 | — | 37.0% | ||
| Q4 25 | -65.7% | -45.9% | ||
| Q3 25 | -100.6% | 53.2% | ||
| Q2 25 | -80.2% | 86.4% | ||
| Q1 25 | -269.9% | -43.4% | ||
| Q4 24 | -54.8% | -2.3% | ||
| Q3 24 | -88.3% | 55.8% | ||
| Q2 24 | -35.0% | 52.5% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | 0.7% | 0.6% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.1% | 5.2% | ||
| Q1 25 | 1.5% | 0.3% | ||
| Q4 24 | 0.1% | 0.7% | ||
| Q3 24 | 0.6% | 0.2% | ||
| Q2 24 | 0.2% | 2.3% |
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
